Jun 8, 2022 · Whether the potential synergy between dose-dense paclitaxel and bevacizumab seen in the setting of platinum-resistant recurrent ovarian cancer will improve outcomes in first …

The ICON8B study found that giving bevacizumab and weekly chemotherapy (Group 3) was more effective at preventing the cancer coming back or getting worse compared to the standard …

Sep 22, 2019 · ICON8B. A phase 3 randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first …

ICON8B, a 3-arm trial, compared BEV+q3wCT versus (vs) BEV+q3wCddwT vs q3wCddwT in high-risk stage III (residual disease >1cm diameter after primary surgery or requirement for …

ICON8B: A trial of chemotherapy and bevacizumab in ovarian cancer. Trial at a glance. Closed trial. Cancer type: Epithelial – high-grade serous and endometrioid; Treatment stage: Primary …

ICON8B is a randomised two-arm, Gynaecologic Cancer Intergroup (GCIG) phase III trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared …

icon8/icon8b An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as …

ICON8B: A phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to standard three weekly chemotherapy and …

Download design elements for free: icons, photos, vector illustrations, and music for your videos. All the assets made by designers → consistent quality ⚡️.

A phase III randomised trial investigating the combination of dose-fractionated chemotherapy & bevacizumab compared to either strategy alone for the first line treatment of women with …